Support Séralini Team for GMO Risk Research - CRIIGEN
Help CRIIGEN

Genetically modified crop consumption at large scale: Possible negative health impacts due to holes in assessment. Overview of the safety studies of GMOs performed on mammals

Tuesday 1 June 2010

Breckling, B. & Verhoeven, R. (2010) Implications of GM-Crop Cultivation at Large Spatial Scales. Theorie in der Ökologie 16. Frankfurt, Peter Lang.


Genetically modified crop consumption at large scale: Possible negative health impacts due to holes in assessment. Overview of the safety studies of GMOs performed on mammals 1

 

Gilles-Eric Séralini a,b , Joël Spiroux de Vendomois b , Dominique Cellier b,c , Robin Mesnage a,b & Emilie Clair a,b
( a University of Caen, Risk Pole CNRS, Caen cedex; b CRIIGEN, Paris; c LITIS, University of Rouen; France.)

 

Background, aim and scope


Recently, a debate on international regulation is ongoing on the capacity to predict and avoid adverse effects on health and environment of new products and novel food/feed (GMOs, chemicals, pesticides, nanoparticles ...). The health risks assessment cannot avoid the study of blood analyses of mammals eating these products in subchronic or chronic tests. Mammalian feeding trials have thus been usually performed for regulatory
purposes, in order to obtain authorizations or commercialization for GM plant derived foods or feed. They may have been published in the scientific literature afterwards. We have obtained, following Court actions or official requests, the raw data of several safety, 28 day or 90 day long, in vivo tests on rats for GMOs (Séralini et al. 2007; Spiroux de Vendomois et al. 2009). We have thoroughly reviewed these tests from both a biological and biostatistical point of view. We focus here on the results of available 90-day feeding trials (or more) with commercialized GMOs, in the light of modern scientific knowledge.

 

Read Online : http://www.gmoseralini.org/wp-content/uploads/2013/01/Seralinial.GMLS2_2010.pdf